HealthEquity Inc. (HQY)
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is HealthEquity (HQY) a Solid Growth Stock? 3 Reasons to Think "Yes"
HealthEquity (HQY) possesses solid growth attributes, which could help it handily outperform the market.
HealthEquity (HQY) Moves to Buy: Rationale Behind the Upgrade
HealthEquity (HQY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HealthEquity Stock Gains as Q3 Earnings Beat Estimates, Revenues Up Y/Y
HQY stock gains post Q3 results as earnings and revenue top estimates, supported by rising HSAs and stronger margins.
HealthEquity, Inc. (HQY) Q3 2026 Earnings Call Transcript
HealthEquity, Inc. (HQY) Q3 2026 Earnings Call Transcript
HealthEquity (HQY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for HealthEquity (HQY) give insight into how the company performed in the quarter ended October 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
HealthEquity (HQY) Tops Q3 Earnings and Revenue Estimates
HealthEquity (HQY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to earnings of $0.78 per share a year ago.
HealthEquity: Flywheel Keeps Spinning
HealthEquity, Inc. remains an asset-light growth opportunity, with a $120/share price target supported by strong Q2 FY26 results. HQY's recurring, asset-linked revenues, 70%+ gross margins, and expanding HSA penetration drive robust returns and positive operating leverage. Management's disciplined capital allocation, improving cost structure, and new legislative tailwinds expand HQY's total addressable market and growth runway.
Exploring Analyst Estimates for HealthEquity (HQY) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of HealthEquity (HQY) for the quarter ended October 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
